Humira market biosimilar share

In the first half of the year, Samsung Epis Adalloce sales were 5.8 billion won and Celltrion Yuflyma was 800 million won

Original Humira maintains quarterly sales of around 22 billion won after drug price cut

Two years have passed since the biosimilar of the autoimmune disease treatment Humira was launched in the domestic market, and its share in the adalimumab market was found to be around 14%.

 

According to IQVIA, a pharmaceutical market research firm, on the 2nd, the market for 'Adalimumab' ingredients in the first half of this year was 50.1 billion won, a 9.9% increase from 45.6 billion won in the first half of last year.

 

Adalimumab is a TNF-alpha inhibitor that treats autoimmune diseases such as rheumatoid arthritis and psoriasis.

 

AbbVie's Humira is the original drug.

 

It was well known as the product with the highest sales in the world until last year.

 

In Korea, sales were 104 billion won in 2020, 92.4 billion won in 2021, and 93.8 billion won in 2022.

 

In particular, the decline in sales in 2021 compared to 2020 is large because the drug price was reduced by 30% with the release of Humira biosimilar.

 

Samsung Bioepis launched Adalloce as a Humira biosimilar in the third quarter of 2021.

 

Then, in the third quarter of last year, Celltrion released Yuflyma.

 

Although two years have passed since launch, the market share of the two biosimilars appears to be only around 14%.

 

This is in contrast to the Avastin biosimilar, which increased its market share in the Bevacizumab market to more than 35% within two years of its launch.

 

Samsung Bioepis Adalloce recorded sales of 5.8 billion won in the first half of last year, more than doubling from KRW 2.7 billion in the same period last year.

 

Cumulative sales exceeded 10 billion won in the first quarter of this year and accumulated 14.5 billion won by the second quarter.

 

Celltrion Yuflyma has been gradually expanding its influence, posting cumulative sales of 1.3 billion won since its launch in the third quarter of last year.

 

Sales in the first half of this year were 800 million won.

 

In addition, LG Chem has announced the release of a Humira biosimilar.

 

LG Chem applied for product approval for Humira biosimilar ‘LBAL’ at the end of last year.

 

LG Chem confirmed the equivalence and safety of LBAL and the original drug Humira in phase 3 clinical trials conducted in Korea and Japan with its Japanese partner Mochida Pharmaceutical, respectively.

 

In the safety category, the incidence of adverse events (AEs) was similar in the LBAL group and the Humira group.

 

In the case of the original Humira, quarterly sales are maintained at around 22 billion won, except for a 30% price cut following the release of biosimilars.

 

In fact, Humira sales in the first half of last year amounted to 43.4 billion won, a 1.4% increase from 42.9 billion won in the same period last year.

 

Analysis suggests that the company is successfully protecting sales overall despite the launch of biosimilars.